<?xml version="1.0" encoding="UTF-8"?>
<p>Of note, further phase I clinical trials (NCT02269423, NCT02280408) (Table 
 <xref rid="T1" ref-type="table">1</xref>) employing high doses of rVSV-ZEBOV demonstrated dose-dependent induction of GP reactive antibody titers in all participants but only mild adverse events without further cases of arthritis (
 <xref rid="B73" ref-type="bibr">73</xref>).
</p>
